Wall Street analysts forecast that Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) will announce earnings of ($0.71) per share for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for Bellicum Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.79) and the highest estimate coming in at ($0.62). Bellicum Pharmaceuticals reported earnings of ($0.80) per share in the same quarter last year, which would suggest a positive year over year growth rate of 11.3%. The business is expected to issue its next earnings results on Monday, May 14th.
According to Zacks, analysts expect that Bellicum Pharmaceuticals will report full-year earnings of ($2.67) per share for the current year, with EPS estimates ranging from ($3.30) to ($2.22). For the next financial year, analysts anticipate that the firm will post earnings of ($2.61) per share, with EPS estimates ranging from ($3.33) to ($2.11). Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that follow Bellicum Pharmaceuticals.
Bellicum Pharmaceuticals (NASDAQ:BLCM) last issued its earnings results on Tuesday, March 13th. The biopharmaceutical company reported ($0.61) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.69) by $0.08. The business had revenue of ($0.07) million during the quarter, compared to analyst estimates of $0.08 million.
Shares of Bellicum Pharmaceuticals stock traded up $1.39 during midday trading on Thursday, hitting $8.24. The company’s stock had a trading volume of 8,709,033 shares, compared to its average volume of 936,459. The stock has a market cap of $226.61, a PE ratio of -2.90 and a beta of 0.47. The company has a quick ratio of 8.37, a current ratio of 8.37 and a debt-to-equity ratio of 0.41. Bellicum Pharmaceuticals has a 1-year low of $5.02 and a 1-year high of $14.49.
In other Bellicum Pharmaceuticals news, major shareholder Bros. Advisors Lp Baker sold 880,735 shares of the firm’s stock in a transaction dated Friday, January 19th. The stock was sold at an average price of $8.20, for a total transaction of $7,222,027.00. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 18.77% of the stock is currently owned by company insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of BLCM. Point72 Asset Management L.P. bought a new position in Bellicum Pharmaceuticals during the third quarter valued at about $4,723,000. Prosight Management LP bought a new position in shares of Bellicum Pharmaceuticals in the fourth quarter worth about $2,534,000. Millennium Management LLC bought a new position in shares of Bellicum Pharmaceuticals in the fourth quarter worth about $1,045,000. X Square Capital LLC bought a new position in shares of Bellicum Pharmaceuticals in the fourth quarter worth about $544,000. Finally, Schwab Charles Investment Management Inc. increased its stake in shares of Bellicum Pharmaceuticals by 47.1% in the third quarter. Schwab Charles Investment Management Inc. now owns 131,217 shares of the biopharmaceutical company’s stock worth $1,516,000 after purchasing an additional 41,995 shares during the period. Institutional investors own 54.57% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This news story was originally reported by Dakota Financial News and is owned by of Dakota Financial News. If you are reading this news story on another website, it was stolen and reposted in violation of international copyright laws. The correct version of this news story can be read at https://dakotafinancialnews.com/2018/04/13/0-71-earnings-per-share-expected-for-bellicum-pharmaceuticals-inc-blcm-this-quarter.html.
Bellicum Pharmaceuticals Company Profile
Bellicum Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The company's clinical product candidates include BPX-501, an adjunct T cell therapy in multiple Phase I/II clinical trials, administered after allogeneic hematopoietic stem cell transplantation; and BPX-601, a GoCAR-T product candidate in Phase I clinical trial for treating solid tumors expressing the prostate stem cell antigen.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.